Medicenna
Clinical-stage immunotherapy company developing engineered interleukins ('Superkines') using directed evolution and protein engineering to modulate immune responses for oncology and inflammatory indications. Active in preclinical optimization, early-phase clinical development, and multi-site international trials.
Industries
Nr. of Employees
small (1-50)
Medicenna
Patents
IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof
US-12590133-B2
View DetailsUses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof
US-12404497-B2
View DetailsIL-4-fusion formulations for treatment of central nervous system (CNS) tumors
US-12274735-B2
View Details
IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof
US-12590133-B2
View DetailsUses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof
US-12404497-B2
View DetailsIL-4-fusion formulations for treatment of central nervous system (CNS) tumors
US-12274735-B2
View DetailsProducts
MDNA11 (optimized IL-2 immunotherapy)
An engineered IL-2 variant designed to stimulate cancer-killing immune cells with reduced toxicity and extended dosing interval; being evaluated in a Phase 1/2 multi-site clinical trial (ABILITY).
MDNA55 (interleukin-based program)
Interleukin-based therapeutic program previously advanced into clinical development for recurrent glioblastoma and supported by non-dilutive grant funding.
BiSKITs (multi-functional Superkine constructs)
Platform concept to create multi-functional engineered cytokine constructs for targeted immune modulation and delivery.
MDNA11 (optimized IL-2 immunotherapy)
An engineered IL-2 variant designed to stimulate cancer-killing immune cells with reduced toxicity and extended dosing interval; being evaluated in a Phase 1/2 multi-site clinical trial (ABILITY).
MDNA55 (interleukin-based program)
Interleukin-based therapeutic program previously advanced into clinical development for recurrent glioblastoma and supported by non-dilutive grant funding.
BiSKITs (multi-functional Superkine constructs)
Platform concept to create multi-functional engineered cytokine constructs for targeted immune modulation and delivery.
Expertise Areas
- Immuno-oncology
- Cytokine biology and engineering
- Early-phase clinical trial management
- Protein engineering and pharmacokinetic optimization
Key Technologies
- Directed evolution
- Cytokine/interleukin engineering
- Protein half-life extension
- Immune monitoring assays
News & Updates
Announcement of a collaboration to evaluate MDNA11 in a randomized neoadjuvant combination trial in high-risk, resectable Stage III melanoma.
Recipient of US$14.1M in non-dilutive funding from the Cancer Prevention and Research Institute of Texas (CPRIT) to support a Phase 2 clinical trial of an interleukin-based program.
Announcement of a collaboration to evaluate MDNA11 in a randomized neoadjuvant combination trial in high-risk, resectable Stage III melanoma.
Recipient of US$14.1M in non-dilutive funding from the Cancer Prevention and Research Institute of Texas (CPRIT) to support a Phase 2 clinical trial of an interleukin-based program.